TickerTalks
Browse all tickers →
TickerTalks›$SMMT
SMSMMT

Summit Therapeutics Inc.

$SMMT·$12B·Biotechnology·Healthcare
$15.28+0.2%YTD-14.1%1Y-41.1%
Mentions · last 7 days
2026-07-06: 27 posts2026-07-07: 20 posts2026-07-08: 24 posts2026-07-09: 29 posts2026-07-10: 46 posts2026-07-11: 24 posts2026-07-12: 33 posts205+42%
Price updated 13m ago·X counts updated 18h ago
SMSMMT
$SMMTSummit Therapeutics Inc.
$15.28+0.22%205 posts+42%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $SMMT, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeWinding up for a moveAI verdict · as of 2026-07-12

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Summit's two top executives just bought $100M of stock in the open market — a rare high-conviction insider signal before catalysts.

Summit Therapeutics is a US-listed clinical-stage biotech developing ivonescimab, a bispecific antibody licensed from Akeso for non-small-cell lung cancer and other tumor types. The stock is down 41% over the past year, but the recent insider signal is unusually loud.

  • The business is fully pre-revenue: zero revenue last quarter with EPS at -$0.24, and consensus expects revenue to jump from $3M this year to $76M in FY27 and $732M in FY28 — the multi-billion valuation rests entirely on ivonescimab's clinical and commercial progress.
  • The June 12 insider buying is the operative signal: officer and director Robert Duggan bought $49.99M of stock and Mahkam Zanganeh (CEO, also officer and director) bought $49.99M at $13.12 — a combined roughly $100M of open-market purchases in a single day. Follow-on Zanganeh purchase of 100K shares for $1.46M reinforced the pattern.
  • The company's public offering strategy is being funded by insider dollars, not just external capital — Summit priced a common-stock offering in early June that management personally participated in at scale, which is the strongest financial-alignment signal insiders can give.
  • The Goldman Sachs 47th Annual Global Healthcare Conference presentation is a real institutional-visibility milestone, and the setup is being framed by external commentators as a 'high-volatility, catalyst-driven binary bet' — accurate for the setup.
  • Recent analyst framing groups Summit alongside Recursion Pharmaceuticals as one of the top-catalyst biotech names heading into H2 2026.

The August 10 Q2 earnings print is really a pipeline-update event — a positive lung cancer trial data disclosure or a follow-on partnership announcement extends the setup. What could break it: a negative Phase 3 data readout, a competitor announcement (particularly from Akeso itself or the broader PD-1/VEGF class), or a fresh capital raise below the June $13.12 insider purchase price.

Agrees with X sentimentX is decisively bullish on the CEO Mahkam Zanganeh 100K-share buy at $1.46M and the broader lung cancer trial data story — supported by the mechanics (real ~$100M open-market insider purchases on June 12 at $13.12 from Duggan and Zanganeh, real pending Phase 3 catalysts). This is one of the strongest insider-alignment signals I've seen in biotech.

What to watch: August 10 Q2 earnings — a positive lung cancer trial data disclosure or a follow-on partnership announcement extends the setup. A negative Phase 3 data readout, a competitor announcement from Akeso or the PD-1/VEGF class, or a fresh capital raise below the June $13.12 insider purchase price breaks it.

On the calendar: 2026-08-10 — Q2 earnings

earnings soonmassive insider buyingphase3 pipelinebinary catalyst bet

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment10 posts analyzed · as of 2026-07-02

Summit Therapeutics CEO Zanganeh buys 100K shares worth $1.46M open market. Bulls cite lung cancer trial data. Sentiment leans decisively bullish.

Read the AI verdict + X sentiment for $SMMT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech with ivonescimab (anti-PD-1/VEGF bispecific antibody) targeting non-small cell lung cancer.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $SMMT.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $SMMT

Direct beneficiary — Clinical-stage biotech with ivonescimab (anti-PD-1/VEGF bispecific antibody) targeting non-small cell lung cancer; the business model is a direct conduit for the GLP-1 pipeline bifurcation and ADA oral formulation competition.

Top industry ETF

$IBBiShares Biotechnology ETF
+13.2%YTD
+43.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-10.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-248%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-341%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 30, 2026$-0.24$-0.33+27.3%
Q4 2025Feb 23, 2026$-0.29$-0.10-182.5%
Q3 2025Oct 20, 2025$-0.31$-0.18-76.4%
Q2 2025Aug 11, 2025$-0.76$-0.09-736.9%
Next earningsMon, Aug 10·consensus EPS $-0.26

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.24$-92.9M
Q4 FY25$0———$-0.29$-75.8M
Q3 FY25$0———$-0.31$-69.2M
Q2 FY25$0———$-0.56$-49.0M

Forward consensus

5-year forecast · up to 12 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$3.2M$1.7M – $4.6M-$1.09-$1.31 – -$0.9510
FY27$76.1M$64.0M – $88.3M-$1.11-$1.33 – -$0.9910
FY28$731.7M$600.5M – $863.0M-$0.49-$0.99 – $0.2812
FY29$2.0B$1.6B – $2.3B$0.33$0.25 – $0.4011
FY30$3.9B$3.2B – $4.6B$1.72$1.32 – $2.126

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.15%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-4.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-13.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 107.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-1.265-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyJun 12Mahkam ZanganehCEO3.8M sh$50.0MBuyJun 12Robert W DugganCEO3.8M sh$50.0MBuyJun 4Robert W DugganCEO100.0K sh$1.5MBuyJun 4Mahkam ZanganehCEO100.0K sh$1.5MBuyJun 4Soni Manmeet SinghCFO50.0K sh$722K

See when $SMMT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 128-K — Item 5.07: Shareholder vote
AI summary

Summit Therapeutics held its 2026 Annual Meeting on June 10, 2026, electing all 9 director nominees including Robert Duggan and Mahkam Zanganeh; ratified PricewaterhouseCoopers LLP as independent auditor; approved advisory executive compensation; and approved an 8,000,000-share increase to the 2020 Stock Incentive Plan. The share plan expansion is a standard governance action but represents moderate additional dilution to existing shareholders.

8-KPress release / Reg FDJun 118-K — Item 7.01: Press release / Reg FD
AI summary

Summit Therapeutics Inc. withdrew its previously announced proposed underwritten public offering of securities, effective June 10, 2026, citing market conditions. No securities were sold under the proposed offering. The filing is a Reg FD furnishing (Item 7.01) and therefore not filed for Exchange Act Section 18 liability purposes. The withdrawal avoids near-term dilution but signals management chose not to press forward in current market conditions, leaving the company's capital position unchanged.

424B5Prospectus supplement (offering)Jun 10424B5
AI summary

Summit Therapeutics filed a preliminary 424B5 on June 9, 2026, offering $500 million of common stock at an assumed price of $14.11 per share (approximately 35.4 million shares), with a 30-day underwriter option for up to an additional $75M in shares. Underwriters are J.P. Morgan, Goldman Sachs, and Citigroup; the offering is structured off a shelf registration (File No. 333-296642). Use of proceeds was not detailed in the excerpt but is specified in the full supplement. This is a sizeable dilutive primary offering for a clinical-stage biotech, representing a meaningful share count increase and placing near-term dilution pressure on existing holders.

S-3ASRAuto-shelf registrationJun 9S-3ASR
AI summary

Summit Therapeutics Inc. filed an automatic shelf registration (S-3ASR) on June 9, 2026, registering common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, and units for future sale by the company or selling stockholders. As a large accelerated filer, the shelf is effective immediately upon filing. This is an evergreen financing shelf — no immediate dilution, but it positions SMMT to raise capital or facilitate secondary sales quickly.

8-KPress release / Reg FDFeb 238-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
+ 11 other (3 routine 8-Ks · 2 proxys · 1 10-Q · 1 earnings 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?fool.com·13d agoSummit Therapeutics: High-Volatility, Catalyst-Driven Binary Betseekingalpha.com·21d agoSummit Therapeutics Announces Proposed Public Offering of Common Stockbusinesswire.com·34d agoSummit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·35d agoMizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech247wallst.com·36d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$AURA$MRNA$SLS$IBRX$REGN$ALLO$CRNX
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport